Results demonstrated that finerenone reduced biomarkers such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and BNP to a degree comparable to spirolactone, while exhibiting lower rates of hyperkalemia and worsening renal function events (Pitt et al., 2013). This evidence concerns the gene NPPB and Hyperkalemia.